All In MedTech

FDA Clearance Tracker · P910056-S051

enVista Hydrophobic Acrylic Intraocular Lens

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 21, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 21, 2023

Approved

Time to decision

216 days

Received Jan 17, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P910056-S051
Device name
enVista Hydrophobic Acrylic Intraocular Lens
Applicant location
Irvine, CA
Received
Jan 17, 2023
Decided
Aug 21, 2023
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P910056

Device type

Device class
Class III
Regulation
21 CFR 886.3600
Specialty
Ophthalmology

Every decision under product code HQL

FDA's approval statement

As written in FDA's record.

Approval for the introduction of the UV + Duo material across the entire enVista® IOL portfolio along with the additions to the model number configurations, introduction of two additional IOL models (the enVista® ASPIRE monofocal [EA] and the enVista® ASPIRE toric [ETA]), and the inclusion of the option to have an electronic Instructions for Use (eIFU).

Source documents

Other decisions for Bausch & Lomb, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.